Related Experiment Video
Updated: Aug 13, 2026
An Electrochemiluminescence-Based Assay for MeCP2 Protein Variants
Published on: May 22, 2020
The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression
Qiang Chang1, Gargi Khare, Vardhan Dani
1Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, USA.
Abstract:
Mutations in the MECP2 gene cause Rett syndrome (RTT). Bdnf is a MeCP2 target gene; however, its role in RTT pathogenesis is unknown. We examined Bdnf conditional mutant mice for RTT-relevant pathologies and observed that loss of BDNF caused smaller brain size, smaller CA2 neurons, smaller glomerulus size, and a characteristic hindlimb-clasping phenotype. BDNF protein level was reduced in Mecp2 mutant mice, and deletion of Bdnf in Mecp2 mutants caused an earlier onset of RTT-like symptoms. To assess whether this interaction was functional and potentially therapeutically relevant, we increased BDNF expression in the Mecp2 mutant brain with a conditional Bdnf transgene. BDNF overexpression extended the lifespan, rescued a locomotor defect, and reversed an electrophysiological deficit observed in Mecp2 mutants. Our results provide in vivo evidence for a functional interaction between Mecp2 and Bdnf and demonstrate the physiological significance of altered BDNF expression/signaling in RTT disease progression.
Insights
Loss of Brain-Derived Neurotrophic Factor (BDNF) worsens Rett syndrome (RTT) symptoms in mice. Restoring BDNF levels in Mecp2 mutant mice improved lifespan and neurological function, suggesting BDNF as a therapeutic target for RTT.
Area of Science:
- Neuroscience
- Genetics
- Molecular Biology
Background:
- Mutations in the Methyl CpG Binding Protein 2 (MECP2) gene are the primary cause of Rett syndrome (RTT).
- Brain-Derived Neurotrophic Factor (BDNF) is a known target gene of MeCP2, but its specific role in RTT pathogenesis remains unclear.
- Understanding the interplay between MECP2 and BDNF is crucial for developing effective RTT therapies.
Purpose of the Study:
- To investigate the functional significance of BDNF in the context of RTT.
- To determine if manipulating BDNF levels can ameliorate RTT-associated pathologies in a mouse model.
- To explore the therapeutic potential of targeting the MECP2-BDNF interaction.
Main Methods:
- Utilized conditional mutant mice lacking BDNF (Bdnf conditional mutants) to study RTT-relevant phenotypes.
- Assessed the impact of BDNF deletion in Mecp2 mutant mice on disease onset and severity.
- Employed a conditional Bdnf transgene to overexpress BDNF in the brains of Mecp2 mutant mice.
- Evaluated lifespan, locomotor activity, and electrophysiological deficits in the mouse models.
Main Results:
- Loss of BDNF in mutant mice resulted in smaller brain size, reduced CA2 neuron size, smaller glomeruli, and hindlimb clasping.
- Mecp2 mutant mice exhibited reduced BDNF protein levels.
- Deletion of Bdnf in Mecp2 mutants led to an earlier onset of RTT-like symptoms.
- BDNF overexpression in Mecp2 mutants extended lifespan, rescued locomotor deficits, and reversed electrophysiological abnormalities.
Conclusions:
- This study provides in vivo evidence for a functional interaction between Mecp2 and Bdnf in RTT pathogenesis.
- Altered BDNF expression and signaling significantly impact RTT disease progression.
- Targeting BDNF represents a promising therapeutic strategy for Rett syndrome.
